文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

家庭无创通气联合氧疗与单纯氧疗对急性COPD加重后因再入院或死亡的影响:一项随机临床试验

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01
一句话结论对于急性COPD加重后持续高碳酸血症(PaCO2>53 mmHg)的患者,家庭氧疗联合家庭无创通气较单纯氧疗延长了12个月内再入院或死亡的时间(调整HR 0.49)。

这项随机临床试验纳入116例急性COPD加重后持续高碳酸血症(PaCO2>53 mmHg)的患者,来自英国13个中心,随机分为家庭氧疗联合家庭无创通气组(57例)和单纯家庭氧疗组(59例)。主要终点为12个月内再入院或死亡时间,校正既往COPD入院次数、既往长期氧疗使用、年龄和BMI。联合组中位再入院或死亡时间为4.3个月,单纯氧疗组为1.4个月,调整HR 0.49(95%CI 0.31-0.77;P=0.002)。12个月再入院或死亡风险联合组为63.4%,单纯氧疗组为80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。结论认为,在急性COPD加重后持续高碳酸血症患者中,家庭氧疗基础上加用家庭无创通气延长了12个月内再入院或死亡时间。

要点

  • 纳入标准:急性COPD加重后持续高碳酸血症(PaCO2>53 mmHg),在呼吸性酸中毒缓解后2周至4周评估。
  • 主要终点:家庭氧疗联合无创通气组中位再入院或死亡时间4.3个月 vs 单纯氧疗组1.4个月,调整HR 0.49(95%CI 0.31-0.77;P=0.002)。
  • 12个月再入院或死亡风险:联合组63.4% vs 单纯氧疗组80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。
  • 12个月死亡人数:联合组16例 vs 单纯氧疗组19例。
  • 排除标准包括肥胖(BMI>35)、阻塞性睡眠呼吸暂停综合征或其他原因导致的呼吸衰竭。

适用人群与场景

  • 急性COPD加重后持续高碳酸血症(PaCO2>53 mmHg)的患者,在呼吸性酸中毒缓解后2周至4周评估。
  • 排除标准包括肥胖(BMI>35)、阻塞性睡眠呼吸暂停综合征或其他原因导致的呼吸衰竭。
  • 来自英国13个中心,2010年至2015年招募。

诊断标准与关键阈值

  • 持续高碳酸血症定义为PaCO2>53 mmHg,在呼吸性酸中毒缓解后2周至4周评估。

处置流程与药物剂量

  • 家庭氧疗联合家庭无创通气组:家庭氧疗(中位氧流量1.0 L/min,IQR 0.5-1.5 L/min)联合家庭无创通气,中位呼吸机参数为吸气相气道正压24 cmH2O(IQR 22-26)、呼气相气道正压4 cmH2O(IQR 4-5)、备用呼吸频率14次/分(IQR 14-16)。
  • 单纯家庭氧疗组:家庭氧疗(中位氧流量1.0 L/min,IQR 0.5-2.0 L/min)。

研究设计与关键结果

  • 研究类型:随机临床试验,纳入116例患者(平均年龄67岁,SD 10岁;女性53%;平均BMI 21.6,IQR 18.2-26.1;平均FEV1 0.6 L,SD 0.2 L;平均PaCO2 59 mmHg,SD 7 mmHg),来自英国13个中心。
  • 干预与对照:家庭氧疗联合家庭无创通气组57例 vs 单纯家庭氧疗组59例。
  • 主要终点:中位再入院或死亡时间联合组4.3个月(IQR 1.3-13.8)vs 单纯氧疗组1.4个月(IQR 0.5-3.9),调整HR 0.49(95%CI 0.31-0.77;P=0.002)。
  • 12个月再入院或死亡风险:联合组63.4% vs 单纯氧疗组80.4%,绝对风险降低17.0%(95%CI 0.1%-34.0%)。
  • 12个月死亡人数:联合组16例 vs 单纯氧疗组19例。
  • 完成12个月研究期:联合组36例 vs 单纯氧疗组28例。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性COPD加重后持续高碳酸血症(PaCO2>53 mmHg)且无肥胖(BMI>35)、阻塞性睡眠呼吸暂停综合征或其他原因呼吸衰竭的患者,作者认为在家庭氧疗基础上加用家庭无创通气可延长12个月内再入院或死亡时间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death.

OBJECTIVE: To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent hypercapnia after an acute COPD exacerbation.

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible.

INTERVENTIONS: There were 59 patients randomized to home oxygen alone (median oxygen flow rate, 1.0 L/min [interquartile range {IQR}, 0.5-2.0 L/min]) and 57 patients to home oxygen plus home NIV (median oxygen flow rate, 1.0 L/min [IQR, 0.5-1.5 L/min]). The median home ventilator settings were an inspiratory positive airway pressure of 24 (IQR, 22-26) cm H2O, an expiratory positive airway pressure of 4 (IQR, 4-5) cm H2O, and a backup rate of 14 (IQR, 14-16) breaths/minute.

MAIN OUTCOMES AND MEASURES: Time to readmission or death within 12 months adjusted for the number of previous COPD admissions, previous use of long-term oxygen, age, and BMI.

RESULTS: A total of 116 patients (mean [SD] age of 67 [10] years, 53% female, mean BMI of 21.6 [IQR, 18.2-26.1], mean [SD] forced expiratory volume in the first second of expiration of 0.6 L [0.2 L], and mean [SD] Paco2 while breathing room air of 59 [7] mm Hg) were randomized. Sixty-four patients (28 in home oxygen alone and 36 in home oxygen plus home NIV) completed the 12-month study period. The median time to readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months (IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio of 0.49 (95% CI, 0.31-0.77; P = .002). The 12-month risk of readmission or death was 63.4% in the home oxygen plus home NIV group vs 80.4% in the home oxygen alone group, absolute risk reduction of 17.0% (95% CI, 0.1%-34.0%). At 12 months, 16 patients had died in the home oxygen plus home NIV group vs 19 in the home oxygen alone group.

CONCLUSIONS AND RELEVANCE: Among patients with persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive ventilation to home oxygen therapy prolonged the time to readmission or death within 12 months.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00990132.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Murphy PB, Rehal S, Arbane G, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2017. PMID: 28528348. doi:10.1001/jama.2017.4451

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。